Characteristics of the 10 patients with relapsed PCNSL that received maintenance lenalidomide in CR 2 through 5, after salvage therapy with either high-dose methotrexate or focal irradiation
| Pt . | Age/sex . | Original dx . | Disease site at dx and relapse . | ECOG . | Therapy . | Response duration, mo . |
|---|---|---|---|---|---|---|
| 1 | 45/F | PCNSL | Dx: occipital mass | 3 | MT-R + EA | CR: 2 |
| Progression 1: basal ganglia mass | 2 | γ Knife + lenalidomide maintenance (10 mg/d) | CR: 12 | |||
| 2 | 81/F | PCNSL | Dx: frontal mass | 3 | MT-R (5 g/m2 HD-MTX) | CR: 1 |
| Progression: Frontal DLBCL Mass | 3 | M-R (5 g/m2 × 4 doses HD-MTX) + lenalidomide maintenance (5 mg/d) | CR: 39+ | |||
| 3 | 75/M | PCNSL/IOL | Dx: bilateral IOL + CSF | 3 | MT-R + EA | CR: 38 |
| Progression 1: frontal lobe mass | 3 | MT-R (×8 doses HD-MTX) + lenalidomide maintenance (5 mg/d) | CR: 8 | |||
| 4 | 55/M | PCNSL | Dx: thalamic mass | 2 | MT-R + EA | CR: 7 |
| Progression 2: thalamus/basal ganglia masses | 2 | MT-R (×8 doses HD-MTX) | CR: 8 | |||
| Progression 3: thalamus/basal ganglia | 2 | MT-R (×8 doses HD-MTX) | CR: 3 | |||
| Progression 4: thalamus/basal ganglia | 3 | MT-R (×8 doses HD-MTX) | PR: 2 | |||
| Progression 5: thalamus/basal ganglia | 3 | IFRT 30.6 Gy/17 fx + lenalidomide maintenance (5 mg alternating with 10 mg/d) | CR: 32+ | |||
| 5 | 38/F | PCNSL | Dx: multifocal brain lesions | 3 | MT-R + EA | CR: 2 |
| Progression 1: IOL | 1 | M-R X 3 doses + lenalidomide maintenance (10 mg/d) | CR: 9 | |||
| 6 | 48/F | PCNSL | Dx: basal ganglia | 2 | MT-R + EA | CR: 4 |
| Progression 1: thalamus/basal ganglia | 2 | MT-R + ASCT (TT, Carbo, VP16) | CR: 3 | |||
| Progression 2: Thalamus/basal ganglia | 3 | M-R 4 cycles + lenalidomide maintenance (10 mg/d) | CR: 13 | |||
| 7 | 61/M | PCNSL | Dx: left temporal lobe mass | 2 | MT-R + EA | CR: 10 |
| Progression 1: thalamus mass | 3 | M-R × 8 doses | PR: 1 | |||
| Progression 2: thalamus mass | 3 | IFRT followed by lenalidomide maintenance (5 mg/d) | PR: 2 | |||
| 8 | 78/F | PCNSL | Dx: frontal mass | 2 | MT-R (4 g/m2) | CR: 1 |
| Progression 1: frontal mass | 2 | GK + lenalidomide maintenance (5 mg/d) | CR: 6 | |||
| 9 | 61/F | PVRL | Dx: B IOL | 2 | MT-R + EA, vitrectomy | CR: 1 |
| Progression 1: B IOL | 2 | IFRT + HD-MTX × 3 doses HD-MTX | CR: 9 | |||
| Progression: 2: frontal mass | 2 | GK followed by lenalidomide maintenance (5 mg alternating with 10 mg QOD) | CR: 25+ | |||
| 10 | 73/F | PCNSL | Dx: temporal lobe | 2 | R-MPV + EA (3.5 mg/m2) | CR: 10 |
| Progression 1: bilateral IOL | 2 | M-R (1.5-3 mg/m2 × 6 doses HD-MTX) followed by lenalidomide maintenance (5 mg/d) | CR: 15+ |
| Pt . | Age/sex . | Original dx . | Disease site at dx and relapse . | ECOG . | Therapy . | Response duration, mo . |
|---|---|---|---|---|---|---|
| 1 | 45/F | PCNSL | Dx: occipital mass | 3 | MT-R + EA | CR: 2 |
| Progression 1: basal ganglia mass | 2 | γ Knife + lenalidomide maintenance (10 mg/d) | CR: 12 | |||
| 2 | 81/F | PCNSL | Dx: frontal mass | 3 | MT-R (5 g/m2 HD-MTX) | CR: 1 |
| Progression: Frontal DLBCL Mass | 3 | M-R (5 g/m2 × 4 doses HD-MTX) + lenalidomide maintenance (5 mg/d) | CR: 39+ | |||
| 3 | 75/M | PCNSL/IOL | Dx: bilateral IOL + CSF | 3 | MT-R + EA | CR: 38 |
| Progression 1: frontal lobe mass | 3 | MT-R (×8 doses HD-MTX) + lenalidomide maintenance (5 mg/d) | CR: 8 | |||
| 4 | 55/M | PCNSL | Dx: thalamic mass | 2 | MT-R + EA | CR: 7 |
| Progression 2: thalamus/basal ganglia masses | 2 | MT-R (×8 doses HD-MTX) | CR: 8 | |||
| Progression 3: thalamus/basal ganglia | 2 | MT-R (×8 doses HD-MTX) | CR: 3 | |||
| Progression 4: thalamus/basal ganglia | 3 | MT-R (×8 doses HD-MTX) | PR: 2 | |||
| Progression 5: thalamus/basal ganglia | 3 | IFRT 30.6 Gy/17 fx + lenalidomide maintenance (5 mg alternating with 10 mg/d) | CR: 32+ | |||
| 5 | 38/F | PCNSL | Dx: multifocal brain lesions | 3 | MT-R + EA | CR: 2 |
| Progression 1: IOL | 1 | M-R X 3 doses + lenalidomide maintenance (10 mg/d) | CR: 9 | |||
| 6 | 48/F | PCNSL | Dx: basal ganglia | 2 | MT-R + EA | CR: 4 |
| Progression 1: thalamus/basal ganglia | 2 | MT-R + ASCT (TT, Carbo, VP16) | CR: 3 | |||
| Progression 2: Thalamus/basal ganglia | 3 | M-R 4 cycles + lenalidomide maintenance (10 mg/d) | CR: 13 | |||
| 7 | 61/M | PCNSL | Dx: left temporal lobe mass | 2 | MT-R + EA | CR: 10 |
| Progression 1: thalamus mass | 3 | M-R × 8 doses | PR: 1 | |||
| Progression 2: thalamus mass | 3 | IFRT followed by lenalidomide maintenance (5 mg/d) | PR: 2 | |||
| 8 | 78/F | PCNSL | Dx: frontal mass | 2 | MT-R (4 g/m2) | CR: 1 |
| Progression 1: frontal mass | 2 | GK + lenalidomide maintenance (5 mg/d) | CR: 6 | |||
| 9 | 61/F | PVRL | Dx: B IOL | 2 | MT-R + EA, vitrectomy | CR: 1 |
| Progression 1: B IOL | 2 | IFRT + HD-MTX × 3 doses HD-MTX | CR: 9 | |||
| Progression: 2: frontal mass | 2 | GK followed by lenalidomide maintenance (5 mg alternating with 10 mg QOD) | CR: 25+ | |||
| 10 | 73/F | PCNSL | Dx: temporal lobe | 2 | R-MPV + EA (3.5 mg/m2) | CR: 10 |
| Progression 1: bilateral IOL | 2 | M-R (1.5-3 mg/m2 × 6 doses HD-MTX) followed by lenalidomide maintenance (5 mg/d) | CR: 15+ |
Carbo, carboplatin; IF-RT, involved field radiotherapy; TT, thiotepa.